
Conmed rose 18.2% from $43.95 to $51.94, ahead of the S&P 500's +10.0%. Its worst day was Dec 5 (−9.4%), and its low came Jun 17 at $32.11.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Financial Considerations Related to the ExitGastroenterology product lines are expected to generate $90 million to $95 million in revenue in 2025 with gross margins of approximately 45%.As a result of this strategic
−9.4%, the year's worst day · S&P 500 +0.2%
Story events cover the past 12 months · Times ET
Conmed shares fell 7.9%, while the S&P 500 fell 0.2%.
−7.9% · S&P 500 −0.2%
EPS of $1.43 beat the $1.32 estimate on $373.2M revenue (est. $366.6M); FY revenue guidance of $1.3B–$1.4B against the $1.4B consensus.
−3.6% · S&P 500 −0.2%
EPS of $0.89 beat the $0.82 estimate on $317.0M revenue (est. $310.6M); FY revenue guidance of $1.4B–$1.4B against the $1.4B consensus.
+1.9% · S&P 500 +1.0%
Conmed closed at its lowest level of the year, 26.9% below where the year started.
−7.1% · S&P 500 −1.5%
Conmed shares rose 10.2%, while the S&P 500 fell 0.8%.
+10.2%, on 2M shares, the year's heaviest volume · S&P 500 −0.8%
EPS of $1.38 beat the $1.11 estimate on $343.5M revenue (est. $337.4M); FY revenue guidance of $1.4B–$1.4B against the $1.4B consensus.
+8.7% · S&P 500 +1.7%
EPS of $1.04 beat the $1.00 estimate on $335.6M revenue (est. $336.4M); FY revenue guidance of $1.4B–$1.4B against the $1.4B consensus.
−0.1% · S&P 500 −0.4%
Where it ended: a close of $51.94 on Nov 9, 2026. Up next: Q4 2026 earnings on Jan 27, 2027 (EPS est. $1.27, revenue est. $366.6M).
Nothing in the past 12 months.
All CNMD dividend historyAs of the Nov 9, 2026 close
Replay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for CNMD and SPY from Benzinga historical bars. Not investment advice.